Haemonetics
170 hedge funds and large institutions have $1.78B invested in Haemonetics in 2016 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 84 increasing their positions, 49 reducing their positions, and 11 closing their positions.
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
71% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 49
8% more capital invested
Capital invested by funds: $1.65B → $1.78B (+$129M)
4% more funds holding
Funds holding: 163 → 170 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.24% less ownership
Funds ownership: 101.07% → 100.83% (-0.24%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$64.2M |
| 2 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$12.6M |
| 3 |
Goldman Sachs
New York
|
+$6.83M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.19M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barrow, Hanley, Mewhinney & Strauss
Dallas,
Texas
|
-$59.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.5M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$9.07M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$7.69M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$7.2M |
HAE Hedge Fund Activity: Q1 2016 in Review
170 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q1 2016, worth a combined $1.78B — up 7.8% from $1.65B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new HAE positions and 11 closed out — a net gain of 8 holders — while 84 added to existing stakes and 49 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $64.2M. The largest seller was Barrow, Hanley, Mewhinney & Strauss, exiting entirely with an estimated $59.5M sold.
- 170 institutional investors held Haemonetics (HAE) as of Q1 2016, up from 163 in Q4 2015.
- Funds reported $1.78B of Haemonetics stock for Q1 2016, up 7.8% quarter-over-quarter.
- 19 funds opened new Haemonetics positions in Q1 2016 and 11 closed out, a net change of +8 holders.
- The largest Haemonetics buyer in Q1 2016 was T. Rowe Price Associates, an estimated $64.2M added.
- The largest Haemonetics seller in Q1 2016 was Barrow, Hanley, Mewhinney & Strauss, an estimated $59.5M sold.
Based on aggregated 13F filings for Q1 2016.